SOURCE: Xtalks

Xtalks Webinars

November 24, 2015 07:00 ET

Learn About FDA Waivers for TQT Studies: How Early Precision QT™ for Cardiac Safety Testing Can Elevate Drug Development and Lower Study Costs, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - November 24, 2015) - A drug's propensity to cause QT prolongation has to be carefully evaluated in the course of clinical development, and until recently, regulators have required a designated study, the thorough QT (TQT) study, to rule out a small QT effect. It has however become increasingly clear that the TQT study is overly sensitive and results in a number of false positives, i.e. drugs that are labelled as causing clinically relevant QT prolongation based on a very small effect, which is unlikely to be proarrhythmic.

Exposure response analysis has emerged as an important way to predict drug-induced QT effects in patients and have been widely applied to data from TQT studies. More recently, a collaborative initiative was undertaken between industry, the Cardiac Safety Research Consortium and FDA, to prospectively evaluate whether exposure response analysis applied to data from early clinical trials using intense ECG monitoring with a High Precision QT technique can detect the QT effect of a group of known QT prolonging drugs. The objective was to demonstrate that this approach can exclude small QT effects with the same confidence as in TQT studies and thereby serve as a replacement. The IQ-CSRC study was fully successful and has led to the decision by the ICH E14 group to revise the clinical guidance document.

On Tuesday, December 8, 2015, Dr. Borje Darpo, Chief Scientific Officer at iCardiac Technologies, and Dr. Dr. Emanuel DeNoia, Medical Director at ICON Early Phase Services, will be outlining the results of the IQ-CSRC study, discuss best practices for collection of high precision ECG data at the site and discuss what it will take to obtain a waiver for the TQT study and to which extent there is a remaining role for TQT studies.

To learn more about this complimentary online broadcast visit: Learn About FDA Waivers for TQT Studies: How Early Precision QT™ for Cardiac Safety Testing Can Elevate Drug Development and Lower Study Costs

About Xtalks:
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2015/11/23/11G073291/Images/ICON_logo_200-830120556669.jpg

Contact Information